Keyphrases
5-hydroxytryptamine
9%
Amphetamine
20%
Antidepressants
32%
Antimuscarinics
10%
Binding Site
39%
Bmax
12%
Brain-derived Neurotrophic Factor
10%
Cocaine
8%
Depressed Patients
9%
Dihydrotetrabenazine
11%
Dopamine
11%
Dopamine Transporter
10%
Escitalopram
9%
Herbal Treatment
16%
High Affinity
41%
High-affinity Binding Site
12%
Human Brain
8%
Human Lymphoblastoid Cell Lines
11%
Human Platelets
21%
Hyperforin
8%
Imipramine
86%
Lymphocytes
9%
Major Depressive Disorder
10%
Methylphenidate
12%
Modulatory Effects
8%
Monoamines
16%
Paroxetine
8%
Platelet Membrane
7%
Platelets
93%
Prefrontal Cortex
10%
Psychostimulants
9%
Rasagiline
8%
Rat Brain
41%
Schizophrenia
10%
Schizophrenic Patients
12%
Selective Serotonin Reuptake Inhibitors
23%
Serotonergic System
7%
Serotonin
11%
Serotonin Transporter
37%
Serotonin Uptake
28%
Serum Serotonin
13%
Striatal
13%
Striatum
13%
Synaptic Vesicle
10%
Thiamine
8%
Thiamine Deficiency
8%
Tricyclic Antidepressants
25%
Verapamil
10%
Vesicular Monoamine Transporter
33%
VMAT2
51%
Neuroscience
Amitriptyline
5%
Antidepressant
32%
Anxiety Disorder
7%
Attention Deficit Hyperactivity Disorder
11%
Behavior (Neuroscience)
17%
Binding Site
39%
Brain-Derived Neurotrophic Factor
14%
Cell Line
13%
Cholinergic
6%
Clozapine
6%
Dementia Praecox
21%
Desipramine
6%
Dopamine Transporter
9%
Dopaminergic
20%
Escitalopram
13%
Haloperidol
7%
Hyperforin
8%
Hypothalamus
6%
Imipramine
77%
In Vitro
13%
In Vivo
9%
Levoamphetamine
17%
Lymphocyte
11%
Magnetic Resonance Imaging
5%
Major Depressive Disorder
8%
Methylphenidate
10%
Monoamine
17%
Muscarinic Acetylcholine Receptor
6%
Nucleus Accumbens
6%
Obsessive-Compulsive Disorder
7%
Paroxetine
5%
Platelet
100%
Prefrontal Cortex
12%
Psychostimulant
8%
Rasagiline
8%
Reuptake
6%
Selective Serotonin Reuptake Inhibitor
20%
Serotonergic
10%
Serotonin
19%
Serotonin Transporter
34%
Serotonin Uptake
29%
Social Anxiety Disorder
5%
Striatum
17%
Synaptic Vesicle
10%
Thiamine
8%
Tricyclic Antidepressant
22%
Typical Antipsychotic
7%
Verapamil
8%
Vesicular Monoamine Transporter
30%
Vesicular Monoamine Transporter 2
44%